Dyadic International Inc. (DYAI) - Q3 2024 10-Q Summary
Business Context and Reporting Period
Company: Dyadic International, Inc.
Reporting Period: Quarter ended September 30, 2024 (Q3 2024) and Nine Months Ended September 30, 2024 (YTD).
Business Overview: A global biotechnology company utilizing microbial protein production platforms (C1-cell and Dapibus) for pharmaceutical, animal health, and non-pharmaceutical applications (food, nutrition). The company generates revenue primarily through research collaborations, licensing agreements, and milestone payments.
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Total Revenue | $1,957,500 | $397,060 | $2,678,013 | $2,212,271 |
| Net Loss | $(203,460) | $(1,614,259) | $(4,258,279) | $(4,723,663) |
| Loss Per Share (Basic/Diluted) | $(0.01) | $(0.06) | $(0.15) | $(0.16) |
| Cash & Cash Equivalents | $5,921,614 (as of Sept 30, 2024) | |||
| Short-term Investments | $4,000,832 (as of Sept 30, 2024) | |||
| Total Debt (Convertible Notes) | $5,268,287 (Net carrying value) | |||
| Operating Cash Flow (YTD) | $(3,278,411) | $(5,803,375) |
Material Changes vs. Prior Period
- Revenue Growth: Q3 2024 revenue increased 393% compared to Q3 2023, driven by $1.0 million in license revenue from the Proliant agreement and $425,000 in success fees from the Inzymes agreement. YTD revenue increased 21%.
- Reduced Net Loss: Q3 net loss narrowed significantly to $203k from $1.6M in the prior year. YTD net loss decreased to $4.3M from $4.7M, aided by higher licensing revenue and lower R&D expenses.
- Debt Issuance: In March 2024, the company issued $6.0 million in 8% Senior Secured Convertible Promissory Notes. As of September 30, 2024, $600,000 of principal had been converted into common stock. This introduced interest expense of $302k YTD, which was not present in the prior year.
- Investment Portfolio: Short-term investment securities increased from $0.75M (Dec 2023) to $4.0M (Sept 2024) as the company deployed cash into held-to-maturity securities.
- Expense Management: R&D expenses decreased YTD by $946k due to the winding down of the DYAI-100 COVID-19 vaccine clinical trial activities. G&A expenses increased YTD by $529k due to higher business development, investor relations, and stock-based compensation costs.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management expects existing cash, investments, and proceeds from convertible notes to be sufficient to meet operational requirements for at least the next 12 months. No formal financial guidance was provided.
- Strategic Developments:
- Proliant: Received $1.0M upfront; expects final $500k payment upon productivity threshold. Targeting product launch in H1 2025.
- Inzymes: Received $425k milestone for target yield achievement; developing second enzyme.
- Product Pipeline: Progress reported on DNASE-1, DNA/RNA Polymerases, and recombinant transferrin for cell culture media. Preclinical studies for Mpox vaccine candidate scheduled to begin Q4 2024.
- Risks & Contingencies:
- History of Losses: The company has a history of net losses and relies on capital raises or licensing revenue to fund operations.
- Customer Concentration: Two significant customers accounted for 69.4% of Q3 2024 revenue. Loss of these customers could materially impact operations.
- Convertible Notes: Notes mature in March 2027 but have redemption dates at 26, 29, and 32 months. Conversion price is set at $1.40/share.
Key Facts for Investor Verification
- Revenue Quality: Verify the sustainability of the $1.4M in license revenue recognized in Q3 2024, which was driven by one-time upfront payments and milestone fees rather than recurring product sales.
- Cash Burn Rate: Monitor the net cash used in operating activities ($3.3M YTD) against the current cash balance ($5.9M) and investment portfolio ($4.0M) to assess runway without further dilution or debt.
- Debt Obligations: Confirm the terms of the $5.3M net convertible debt, specifically the 8% cash interest requirement and the potential for future conversion at $1.40/share, which could be dilutive.
- Customer Dependency: Assess the risk associated with two customers representing nearly 70% of Q3 revenue.
- Related Party Transactions: Note that a significant portion of the convertible notes ($2.0M principal) was purchased by related parties (family members/trusts of the CEO).